Immune Pharma (IMNP) Reports Q1 Loss of $0.15/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Immune Pharmaceuticals Reports First Quarter 2015 Financial Results; Bertilimumab Phase II Trials Ready to Enroll Patients
May 18, 2015 7:30 AM EDTNEW YORK, May 18, 2015 /PRNewswire/ --Â Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune") announced financial results for the first quarter ended March 31, 2015. Immune filed its Quarterly Report on Form 10-Q for the first quarter of 2015 on Friday, May 15, 2015.
"In the past quarter, we relocated our leadership team to New York City and accelerated our focus on operational execution. We are now ready to commence patient enrollment in our Phase II clinical trials with bertilimumab, a first in class monoclonal antibody, for the treatment of ulcerative colitis and bullous pemphigoid," said Dr. Daniel... More
